AVEO Pharmaceuticals, Inc.

Symbol: AVEO




Market price today

  • -20.5774

    P/E Ratio

  • 6.5554

    PEG Ratio

  • 521.45M

    MRK Cap

  • 0.00%

    DIV Yield

AVEO Pharmaceuticals, Inc. (AVEO) Stock Price & Analysis

Shares Outstanding


Gross Profit Margin


Operating Profit Margin


Net Profit Margin


Return on Assets


Return on Equity


Return on Capital Employed


Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. Michael Bailey
Full-time employees:114

AVEO Pharmaceuticals, Inc., an oncology-focused biopharmaceutical company, focuses on developing and commercializing medicines for patients with cancer. It markets FOTIVDA, an oral, next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC). The company is also developing tivozanib for the treatment of RCC, hepatocellular carcinoma, ovarian cancer, immunologically cold tumors, and cholangiocarcinoma. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of head and neck squamous cell carcinoma, pancreatic cancer, and acute myeloid leukemia; AV-380, a potent humanized IgG1 inhibitory monoclonal antibody for the treatment or prevention of cachexia; AV-203, a potent humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353 that targets the Notch 3 pathway. The company has collaborations and license agreements with AstraZeneca PLC; EUSA Pharma (UK) Limited; Biodesix, Inc.; CANbridge Life Sciences, Ltd.; Biogen Idec International GmbH; St. Vincent's Hospital Sydney Limited; and Kyowa Kirin Co., Ltd. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

General Outlook

In simple terms, AVEO Pharmaceuticals, Inc. has 34.763 M shares that people are buying and selling right now. When we look at how much money they make before expenses, they keep 0.877% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.239%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.329%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.249% return, is a testament to AVEO Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. AVEO Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -0.786%. Furthermore, the proficiency of AVEO Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable -0.312% return on capital employed.

Stock Prices

AVEO Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $14.94, while its low point bottomed out at $14.86. This variance in figures offers investors a lucid insight into the roller-coaster ride that is AVEO Pharmaceuticals, Inc.'s stock market.
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2023?

There are stock number shares outstanding of AVEO Pharmaceuticals, Inc. (AVEO) on the NASDAQ in 2023.

What is P/E ratio of enterprise in 2023?

The current P/E ratio of enterprise is -20.577 in 2023.

What is the ticker symbol of AVEO Pharmaceuticals, Inc. stock?

The ticker symbol of AVEO Pharmaceuticals, Inc. stock is AVEO.

What is company IPO date?

IPO date of AVEO Pharmaceuticals, Inc. is 2010-03-12.

What is company current share price?

Current share price is 15.000 USD.

What is stock market cap today?

The market cap of stock today is 521446496.000.

What is PEG ratio in 2023?

The current 6.555 is 6.555 in 2023.

What is the number of employees in 2023?

In 2023 the company has 114.